Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lo...

Descripció completa

Dades bibliogràfiques

Autors principals:	Habib Yaribeygi, Mina Maleki, Tannaz Jamialahamdi, Seyed Adel Moallem, Amirhossein Sahebkar
Format:	Artigo
Idioma:	Inglês
Publicat:	IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund 2023-04-01
Col·lecció:	EXCLI Journal : Experimental and Clinical Sciences
Matèries:	diabetes mellitus sodium-glucose cotransporter-2 inhibitors liver non-alcoholic fatty liver disorders fibrosis hepatocellular carcinoma cirrhosis
Accés en línia:	https://www.excli.de/index.php/excli/article/view/6022
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!